Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdosing Psilocybin to Improve Mood in MDD
NCT05259943Phase 2Completed
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD). Started Jul 2023; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05259943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259943.